TECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

22 Aug 24

Updated

08 Jan 26

Views

75

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-9.0%

7D

5.1%

Loading

1Y

-9.0%

7D

5.1%

You can edit this narrative until Jan 9 6:10 AM. Then, changes will post as Updates.

Author's Valuation

US$69.171.1% undervalued

AnalystConsensusTarget Fair Value

Shared on 08 Jan 26

TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook

Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).

Shared on 01 Dec 25

TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook

Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.

Shared on 17 Nov 25

Fair value Increased 1.97%

TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead

Narrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).

Shared on 03 Nov 25

Fair value Increased 1.12%

Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.

Shared on 20 Oct 25

Fair value Increased 1.29%

Narrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.

Shared on 27 Aug 25

Fair value Increased 3.24%

Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.

Shared on 07 May 25

Fair value Decreased 21%

Shared on 30 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

Fair value Decreased 3.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

Fair value Decreased 0.71%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 1.19%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 2.00%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 0.88%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Increased 22%

AnalystConsensusTarget has decreased future PE multiple from 50.9x to 45.3x.

AnalystConsensusTarget Fair Value

US$69.17

1.1% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

6.18%

Life Sciences revenue growth rate

0.27%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.84%

Calculation

US$274.63m

Earnings '29

x

47.06x

PE Ratio '29

=

US$12.92b

Market Cap '29

US$12.92b

Market Cap '29

/

149.18m

No. shares '29

=

US$86.63

Share Price '29

US$86.63 Share Price '29

Discounted to 2026 @ 7.84% p.a.

=

US$69.08

Fair Value '26